{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"MRNA","limit":50},"count":50,"signals":[{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":35,"context":"Related Party Transactions | 33 | | | | | Corporate Responsibility | 34 | | | | | Management | 36 | | | | | PROPOSAL 2 | 38 | | | | | | | Non-binding Advisory Vote to Approve the Compensation of Our Named Executive Officers | | | | | Letter from the Compensation and Talent Committee | 39 | | | | | Executive Compensation | 42 | | | | | Compensation and Talent Committee Report | 77 | | | | | Security Ownership of Certain","filed_date":"2026-03-16","accession":"0001308179-26-000081","full_text":"https://origin.rootz.global/static/filing/0001308179-26-000081.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":22,"context":"Compliance with these requirements may require substantial investments in governance, documentation, monitoring, testing, or operational controls, and may limit our ability to deploy or scale certain AI-enabled tools or features. In addition, bad actors globally use increasingly sophisticated methods, including AI Technologies, to engage in illegal activities involving the theft and misuse of personal informatio","filed_date":"2026-02-20","accession":"0001682852-26-000033","full_text":"https://origin.rootz.global/static/filing/0001682852-26-000033.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":70,"context":"e the negotiating leverage such entities have over us and other drug manufacturers. Additional discounts, rebates, coverage or plan changes, restrictions or exclusions as described above could have a material adverse effect on sales of our affected products, particularly our therapeutic products or those that are individualized for a particular patient. Coverage and reimbursement by a third-party payor may depend on var","filed_date":"2026-02-20","accession":"0001682852-26-000033","full_text":"https://origin.rootz.global/static/filing/0001682852-26-000033.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":57,"context":"| | | 4.2Due Authorization | 106 | | | 4.3No Conflict Government Consents | 106 | | | 4.4Binding Obligation | 107 | | | 4.5Historical Financial Statements | 107 | | | 4.6Projections | 107 | | | 4.7No Material Adverse Effect | 108 | | | 4.8Adverse Proceedings | 108 | | | 4.9Payment of Taxes | 108 | | | 4.10Ownership of Material Property | 108 | | | 4.11Environmental Matters | 109 | | | 4.12Governmental Regulation | 109 |","filed_date":"2025-11-24","accession":"0001628280-25-053816","full_text":"https://origin.rootz.global/static/filing/0001628280-25-053816.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":21,"context":"ationships and Related Party Transactions | 37 | | | | | ESG Topics | 38 | | | | | Management | 40 | | | | | PROPOSAL 2 | 42 | | | | | | | Non-binding Advisory Vote to Approve the Compensation of Our Named Executive Officers | | | | | Letter from the Compensation and Talent Committee | 43 | | | | | Executive Compensation | 45 | | | | | Compensation and Talent Committee Report | 81 | | | | | Security Ownership of Certain","filed_date":"2025-03-11","accession":"0001308179-25-000082","full_text":"https://origin.rootz.global/static/filing/0001308179-25-000082.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":25,"context":"oduct candidates and technology, including our ability to enter into license agreements, and our expectations regarding pending legal proceedings related to our intellectual property; participant enrollment in our clinical trials, including enrollment demographics and timing;  potential advantages of mRNA as compared to traditional medicine; our ability to successfully commercialize our products, if","filed_date":"2025-02-21","accession":"0001682852-25-000022","full_text":"https://origin.rootz.global/static/filing/0001682852-25-000022.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":66,"context":"e the negotiating leverage such entities have over us and other drug manufacturers. Additional discounts, rebates, coverage or plan changes, restrictions or exclusions as described above could have a material adverse effect on sales of our affected products, particularly our therapeutic products or those that are individualized for a particular patient. Coverage and reimbursement by a third-party payor may depend on var","filed_date":"2025-02-21","accession":"0001682852-25-000022","full_text":"https://origin.rootz.global/static/filing/0001682852-25-000022.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":15,"context":"ese initiatives was quite positive. Most of our investors recognize Modernas important role in promoting access to medicines, particularly through efforts like our mRNA Access program and diverse enrollment targets in our clinical trials. Investors were also supportive of our efforts to provide greater transparency through our ESG Report (which includes SASB and GRI disclosures) and ESG Day. Investor","filed_date":"2024-03-21","accession":"0001308179-24-000208","full_text":"https://origin.rootz.global/static/filing/0001308179-24-000208.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":26,"context":"| | |  |  29 |  |  ESG Topics |  | | |  |  |  |  |  | | |  |  33 |  |  Management |  | | |  |  |  |  |  | | |  |  35 |  |  Proposal No. 2: Non-binding Advisory Vote to Approve the Compensation of our Named Executive Officers |  | | |  |  |  |  |  | | |  |  36 |  |  Letter from the Compensation and Talent Committee |  | | |  |  |  |  |  | | |  |  38 |  |  Executive Compensation |  | | |  |  |  |  |  | | |  |  73 |  |  Co","filed_date":"2024-03-21","accession":"0001308179-24-000208","full_text":"https://origin.rootz.global/static/filing/0001308179-24-000208.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":21,"context":"ogress, completion, results (including interim data) and cost of our clinical trials, preclinical studies and research and development programs, as well as those of our collaborators; participant enrollment in our clinical trials, including enrollment demographics and timing;  potential advantages of mRNA as compared to traditional medicine; our ability to obtain and maintain regulatory approval for","filed_date":"2024-02-23","accession":"0001682852-24-000015","full_text":"https://origin.rootz.global/static/filing/0001682852-24-000015.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":67,"context":"e the negotiating leverage such entities have over us and other drug manufacturers. Additional discounts, rebates, coverage or plan changes, restrictions or exclusions as described above could have a material adverse effect on sales of our affected products, particularly our therapeutic products or those that are individualized for a particular patient. Coverage and reimbursement by a third-party payor may depend upon a","filed_date":"2024-02-23","accession":"0001682852-24-000015","full_text":"https://origin.rootz.global/static/filing/0001682852-24-000015.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"ommunities and vulnerable populations. When we recognized minority under-representation in the Phase 3 study of mRNA-1273, our original COVID-19 vaccine, we decided to slow down the overall study enrollment to ensure diverse representation. At the conclusion of enrollment, the study included more than 11,000 participants from communities of color, representing 37% of the study population. For the Pha","filed_date":"2023-03-15","accession":"0001308179-23-000184","full_text":"https://origin.rootz.global/static/filing/0001308179-23-000184.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":25,"context":"Certain Relationships and Related Party Transactions |  |  | | 28 |  ESG Topics |  |  | | 32 |  Management |  |  | | 35 |  Proposal No. 2 Non-binding Advisory Vote to Approve the Compensation of our Named Executive Officers |  |  | | 36 |  Executive Compensation |  |  | | 69 |  Compensation and Talent Committee Report |  |  | | 70 |  Security Ownership of Certain Beneficial Owners and Management |  |  | | 72 |  Proposa","filed_date":"2023-03-15","accession":"0001308179-23-000184","full_text":"https://origin.rootz.global/static/filing/0001308179-23-000184.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":19,"context":"im data) and cost of our clinical trials, preclinical studies and research and development programs, as well as those of our collaborators, including Merck and Vertex Pharmaceuticals; participant enrollment in our clinical trials, including enrollment demographics and timing;  our ability to identify research priorities and apply a risk-mitigated strategy to efficiently discover and develop developme","filed_date":"2023-02-24","accession":"0001682852-23-000011","full_text":"https://origin.rootz.global/static/filing/0001682852-23-000011.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":41,"context":"seen challenges; Preclinical development is lengthy and uncertain, especially for mRNA medicines, and our preclinical programs or development candidates may be delayed or terminated, which may have a material adverse impact on our platform or our business; Clinical development is lengthy and uncertain, and our clinical programs may be delayed or terminated, or may be more costly to conduct than we anticipate, any of whi","filed_date":"2023-02-24","accession":"0001682852-23-000011","full_text":"https://origin.rootz.global/static/filing/0001682852-23-000011.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":28,"context":"| | 23 |  Certain Relationships and Related Party Transactions |  | | 25 |  ESG Topics |  | | 29 |  Management |  | | 31 |  Proposal No. 2 Non-binding Advisory Vote to Approve the Compensation of our Named Executive Officers |  | | 32 |  Executive Compensation |  | | 60 |  Compensation Committee Report |  | | 61 |  Security Ownership of Certain Beneficial Owners and Management |  | | 63 |  Proposal No. 3 Ratification of","filed_date":"2022-03-09","accession":"0001308179-22-000041","full_text":"https://origin.rootz.global/static/filing/0001308179-22-000041.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":19,"context":"ed in response, material delays in diagnoses, initiation or continuation of treatment for diseases that may be addressed by our development candidates and investigational medicines, or in patient enrollment in clinical trials, potential clinical trials, regulatory review or supply chain disruptions, and other potential impacts to our business, the effectiveness or timeliness of steps taken by us to m","filed_date":"2022-02-25","accession":"0001682852-22-000012","full_text":"https://origin.rootz.global/static/filing/0001682852-22-000012.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":35,"context":"lly for a new class of medicines such as mRNA, and therefore our preclinical programs or development candidates may be delayed, terminated, or may never advance to the clinic, any of which may have a material adverse impact on our platform or our business; Clinical development is lengthy and uncertain, especially with a new class of medicines such as mRNA medicines. Clinical trials of our investigational medicines may b","filed_date":"2022-02-25","accession":"0001682852-22-000012","full_text":"https://origin.rootz.global/static/filing/0001682852-22-000012.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":26,"context":"arty Transactions |  | |  |  | | | 23 |  Key Sustainability Topics |  | |  |  | | | 25 |  Management |  | |  |  | | | 28 |  Proposal No. 2 Non-binding Advisory Vote to Approve the Compensation of our Named Executive Officers |  | |  |  | | | 29 |  Executive Compensation |  | |  |  | | | 53 |  Compensation Committee Report |  | |  |  | | | 54 |  Security Ownership of Certain Beneficial Owners and Management |  | |  |  |","filed_date":"2021-03-10","accession":"0001308179-21-000031","full_text":"https://origin.rootz.global/static/filing/0001308179-21-000031.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":28,"context":"ed in response, material delays in diagnoses, initiation or continuation of treatment for diseases that may be addressed by our development candidates and investigational medicines, or in patient enrollment in clinical trials, potential clinical trials, regulatory review or supply chain disruptions, and other potential impacts to our business, the effectiveness or timeliness of steps taken by us to m","filed_date":"2021-02-26","accession":"0001682852-21-000006","full_text":"https://origin.rootz.global/static/filing/0001682852-21-000006.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":47,"context":"lly for a new class of medicines such as mRNA, and therefore our preclinical programs or development candidates may be delayed, terminated, or may never advance to the clinic, any of which may have a material adverse impact on our platform or our business; Clinical development is lengthy and uncertain, especially with a new class of medicines such as mRNA medicines. Clinical trials of our investigational medicines may b","filed_date":"2021-02-26","accession":"0001682852-21-000006","full_text":"https://origin.rootz.global/static/filing/0001682852-21-000006.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"development efforts, including retention (both for executives and non-executive employees), development and performance managementOversight of human capital strategy, including the implementation of AI-enabled tools and digital capabilities to enhance workforce productivity and organizational effectivenessOngoing development of our future operating model as we seek to grow sustainably and execute our near-term","filed_date":"2026-03-16","accession":"0001308179-26-000081","full_text":"https://origin.rootz.global/static/filing/0001308179-26-000081.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"cal candidates or campaigns. |  | | Clinical Trial Oversight |  Enhanced governance and oversight by the Product Development Committee. Launched pivotal studies for CMV and RSV, setting diversity enrollment targets in CMV trials within the U.S. |  | &#xa0; Compensation Highlights | Introduction  of PSUs |  In 2021, implemented performance-based restricted stock units (PSUs) for CEO and Executive Comm","filed_date":"2022-03-09","accession":"0001308179-22-000041","full_text":"https://origin.rootz.global/static/filing/0001308179-22-000041.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"tion 302 or 303 of ERISA with respect to any Pension Plan (whether or not waived in accordance with Section 412(c) of the Internal Revenue Code) or the failure to make by its due date a required installment under Section 430(j) of the Internal Revenue Code with respect to any Pension Plan or the failure to make any required contribution to a Multiemployer Plan (c) the provision by the administrator o","filed_date":"2025-11-24","accession":"0001628280-25-053816","full_text":"https://origin.rootz.global/static/filing/0001628280-25-053816.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"associated with the vaccines development. Our Board and COVID Committee were also engaged in high-level decisions related to our clinical trials, including our decision in September 2020 to slow enrollment in the Phase 3 clinical trial to ensure that participants were representative of the diversity of the communities impacted by COVID-19. As we continued to receive favorable data from our clinical","filed_date":"2021-03-10","accession":"0001308179-21-000031","full_text":"https://origin.rootz.global/static/filing/0001308179-21-000031.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"programs until revenues increase. These prioritization efforts are expected to put Moderna on a path to decrease annual R&D expenses by approximately $1 billion in 2027 compared to 2024. Digital and AI-Driven Productivity: During 2024, the Company reduced SG&A expenses by 24% year-over-year, driven in part by the utilization of digital  tools to increase efficiency. In November 2024, TraceyFranklin, our Chief Hum","filed_date":"2025-03-11","accession":"0001308179-25-000082","full_text":"https://origin.rootz.global/static/filing/0001308179-25-000082.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":72,"match_count":9,"context":"panies through early stage growth to maturity and operating as public companies. He has particular insight into how digital technology can facilitate scaling and growth, while also protecting against cybersecurity threats. His experience as an executive, director and advisor to both public and private companies provides expertise, particularly in finance and accounting, human capital management and the","filed_date":"2024-03-21","accession":"0001308179-24-000208","full_text":"https://origin.rootz.global/static/filing/0001308179-24-000208.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":64,"match_count":8,"context":"d Technology Committee | | | | | Age | Skills and ExperienceOur directors represent a diverse range of skills and experience | | | CEO Experience | | 8/9 | | | Commercialization | | 5/9 | | | Digital/Cyber/AI | | 5/9 | | | Drug Development | | 6/9 | | | Finance/Accounting | | 8/9 | | | Tenure | Government/Regulatory | | 7/9 | | | Healthcare Industry | | 8/9 | | | Human Capital Management | | 8/9 | | |","filed_date":"2025-03-11","accession":"0001308179-25-000082","full_text":"https://origin.rootz.global/static/filing/0001308179-25-000082.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":64,"match_count":8,"context":"s of such written request) that (a) such proposed nominee is not and will not become party to any agreement, arrangement or understanding with any person or entity as to how such proposed nominee, if elected as a director of the Corporation, will act or vote on any issue or question (a Voting Commitment) that has not been disclosed to the Corporation in the questionnaire described in clause (v) herein (b) such propose","filed_date":"2024-05-09","accession":"0001682852-24-000031","full_text":"https://origin.rootz.global/static/filing/0001682852-24-000031.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_concentration","strength":63,"match_count":1,"context":"grants made by government-sponsored and private organizations, and to a lesser extent, strategic alliances in 2021 and 2020. Historically, we generated revenue primarily from strategic alliances.  A significant portion of our revenue to date has been generated from the following entities that accounted for more than 10% of total revenue and accounts receivable for the periods presented: | | | | | | | | | | | | | | | | | | | | | |","filed_date":"2022-02-25","accession":"0001682852-22-000012","full_text":"https://origin.rootz.global/static/filing/0001682852-22-000012.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_concentration","strength":63,"match_count":1,"context":"duct sales to the U.S. Government and international government agencies, and to a lesser extent, strategic alliances in 2020. Historically, we generated revenue primarily from strategic alliances.  A significant portion of our revenue to date has been generated from the following entities that accounted for more than 10% of total revenue and accounts receivable for the periods presented: | | | | | | | | | | | | | | | | | | | | | |","filed_date":"2021-02-26","accession":"0001682852-21-000006","full_text":"https://origin.rootz.global/static/filing/0001682852-21-000006.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":56,"match_count":7,"context":"a diverse range of skills and experience | | | | CEO Experience | 8/9 | | Healthcare Industry | 8/9 | | | | | | | | Commercialization | 5/9 | | Human Capital Management | 8/9 | | | | | | | | Digital/Cyber/AI | 5/9 | | International Experience | 8/9 | | | | | | | | Drug Development | 6/9 | | Investor Experience | 7/9 | | | | | | | | Finance/Accounting | 8/9 | | Manufacturing/Supply Chain | 4/9 | | | |","filed_date":"2026-03-16","accession":"0001308179-26-000081","full_text":"https://origin.rootz.global/static/filing/0001308179-26-000081.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":56,"match_count":7,"context":"essary to fully comply with, or be exempt from, Section 409A of the Code and all related rules and regulations.  (b) Anything in this Agreement to the contrary notwithstanding, if at the time of your separation from service within the meaning of Section 409A of the Code you are a specified employee within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that you beco","filed_date":"2022-06-01","accession":"0001193125-22-165220","full_text":"https://origin.rootz.global/static/filing/0001193125-22-165220.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":56,"match_count":7,"context":"of herpes lesions due to HSV-2 | | |  |  |  |  Announcing a new Varicella-zoster virus (VZV) vaccine candidate (mRNA-1468) designed to reduce the rate of herpes zoster (shingles) | | |  |  |  |  Enrollment in Phase 1 study of Epstein Barr virus (EBV) vaccine candidate (mRNA-1189) is ongoing | | |  |  |  |  Enrollment in Phase 3 pivotal registration study of cytomegalovirus (CMV) vaccine candidate (m","filed_date":"2022-02-24","accession":"0001193125-22-051058","full_text":"https://origin.rootz.global/static/filing/0001193125-22-051058.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"margin_pressure","strength":48,"match_count":6,"context":"rmaceutical companies, biotechnology companies, academic institutions, government agencies and public and private research institutions. The continued growth of the mRNA field is leading to increased competitive pressure, including from large and more established pharmaceutical companies. We also face competition when entering into strategic alliances to advance and grow our pipeline.  Seasonal vaccines We largely co","filed_date":"2026-02-20","accession":"0001682852-26-000033","full_text":"https://origin.rootz.global/static/filing/0001682852-26-000033.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":48,"match_count":6,"context":"rolled, ongoing Phase 1 trial in pediatric populations. No cases of Guillain-Barre Syndrome (GBS) had been reported with mRNA-1345 in the Phase 3 RSV trial as of the April 30th cutoff date. 1 Flu Enrollment has been successfully completed in the Companys Phase 3 immunogenicity trial (P303) for an enhanced formulation of mRNA-1010. This updated formulation is anticipated to generate an improved immune","filed_date":"2023-08-03","accession":"0001682852-23-000025","full_text":"https://origin.rootz.global/static/filing/0001682852-23-000025.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":48,"match_count":6,"context":"ed in response, material delays in diagnoses, initiation or continuation of treatment for diseases that may be addressed by our development candidates and investigational medicines, or in patient enrollment in clinical trials, potential clinical trials, regulatory review or supply chain disruptions, and other potential impacts to our business, the effectiveness or timeliness of steps taken by us to m","filed_date":"2021-11-04","accession":"0001682852-21-000027","full_text":"https://origin.rootz.global/static/filing/0001682852-21-000027.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":40,"match_count":5,"context":"results, and cost of our clinical trials, preclinical studies and research and development programs, as well as those of our collaborators, including Merck and Vertex Pharmaceuticals; participant enrollment in our clinical trials, including enrollment demographics and timing; potential advantages of mRNA as compared to traditional medicine; our ability to obtain and maintain regulatory approval of ou","filed_date":"2023-05-04","accession":"0001682852-23-000021","full_text":"https://origin.rootz.global/static/filing/0001682852-23-000021.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_concentration","strength":38,"match_count":1,"context":"ent, stand-ready manufacturing revenue from international government entities, grants made by government-sponsored and private organizations, and collaboration revenue from our strategic alliances. A significant portion of our revenue to date has been generated from the following entities that accounted for more than 10% of total revenue and accounts receivable for the periods presented: | | | PercentageofRevenueYearsEndedDecember","filed_date":"2026-02-20","accession":"0001682852-26-000033","full_text":"https://origin.rootz.global/static/filing/0001682852-26-000033.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_concentration","strength":38,"match_count":1,"context":"distributors and other governments and organizations, and to a lesser extent, grants made by government-sponsored and private organizations, and collaboration revenue from our strategic alliances. A significant portion of our revenue to date has been generated from the following entities that accounted for more than 10% of total revenue and accounts receivable for the periods presented: | | | PercentageofRevenueYearsEndedDecember","filed_date":"2025-02-21","accession":"0001682852-25-000022","full_text":"https://origin.rootz.global/static/filing/0001682852-25-000022.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_concentration","strength":38,"match_count":1,"context":"stributors and other governments and organizations, and to a lesser extent, grants made by government-sponsored and private organizations, and collaboration revenue from our strategic alliances. 113A significant portion of our revenue to date has been generated from the following entities that accounted for more than 10% of total revenue and accounts receivable for the periods presented: | | | PercentageofRevenueYearsEndedDecember","filed_date":"2024-02-23","accession":"0001682852-24-000015","full_text":"https://origin.rootz.global/static/filing/0001682852-24-000015.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_concentration","strength":38,"match_count":1,"context":"product sales to the U.S. Government, other international governments and organizations, grants made by government-sponsored and private organizations, and to a lesser extent, strategic alliances.  A significant portion of our revenue to date has been generated from the following entities that accounted for more than 10% of total revenue and accounts receivable for the periods presented: | | | | | | | | | | | | | | | | | | | | | |","filed_date":"2023-02-24","accession":"0001682852-23-000011","full_text":"https://origin.rootz.global/static/filing/0001682852-23-000011.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":36,"match_count":2,"context":"30, 2025, or as of the date otherwise set forth below, for each person or group of affiliated persons known by us to be the beneficial owner of more than five percent of our capital stock each of our named executive officers each of our directors and all of our executive officers and directors as a group. Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investme","filed_date":"2025-10-15","accession":"0001682852-25-000062","full_text":"https://origin.rootz.global/static/filing/0001682852-25-000062.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":33,"match_count":1,"context":"uiring all outstanding shares of OriCiro Genomics K.K. for a cash consideration of $86million. As a result of this acquisition, we recognized $52million in goodwill and an intangible asset related to acquired technology valued at $48million, which are included within other non-current assets in our consolidated balance sheets. This acquisition provided us with tools for cell-free synthesis and amplification of plasmid DNA, a ke","filed_date":"2024-02-23","accession":"0001682852-24-000015","full_text":"https://origin.rootz.global/static/filing/0001682852-24-000015.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"margin_pressure","strength":32,"match_count":4,"context":"rmaceutical companies, biotechnology companies, academic institutions, government agencies and public and private research institutions. The continued growth of the mRNA field is leading to increased competitive pressure, including from large and more established pharmaceutical companies. We also face competition when entering into strategic alliances to advance and grow our pipeline.  We largely compete against Pfiz","filed_date":"2025-02-21","accession":"0001682852-25-000022","full_text":"https://origin.rootz.global/static/filing/0001682852-25-000022.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":32,"match_count":4,"context":"zumab (KEYTRUDA), compared to pembrolizumab alone, for the adjuvant treatment of high-risk resected melanoma is fully enrolled; data readout expected in the fourth quarter of 2022 | | |  |  |  |  Enrollment of the first cohort in Propionic Acidemia candidate (mRNA-3927) Phase 1/2 Paramount study is complete | | |  |  |  |  First patient dosed in Phase 1 study of Methylmalonic Acidemia (MMA) candidate","filed_date":"2021-11-04","accession":"0001193125-21-319285","full_text":"https://origin.rootz.global/static/filing/0001193125-21-319285.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":32,"match_count":4,"context":"ed in response, material delays in diagnoses, initiation or continuation of treatment for diseases that may be addressed by our development candidates and investigational medicines, or in patient enrollment in clinical trials, potential clinical trials, regulatory review or supply chain disruptions, and other potential impacts to our business, the effectiveness or timeliness of steps taken by us to m","filed_date":"2021-08-05","accession":"0001682852-21-000022","full_text":"https://origin.rootz.global/static/filing/0001682852-21-000022.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":31,"match_count":2,"context":"of such matters is inherently uncertain and often involves significant judgment in assessing risk and estimating potential exposure. While we do not currently expect any pending proceedings to have a material adverse effect on our financial position, results of operations, or cash flows, there can be no assurance that future developments will not have a material impact.The following summarizes our significant legal proc","filed_date":"2025-11-06","accession":"0001682852-25-000075","full_text":"https://origin.rootz.global/static/filing/0001682852-25-000075.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":31,"match_count":2,"context":"of such matters is inherently uncertain and often involves significant judgment in assessing risk and estimating potential exposure. While we do not currently expect any pending proceedings to have a material adverse effect on our financial position, results of operations, or cash flows, there can be no assurance that future developments will not have a material impact.The following summarizes our significant legal proc","filed_date":"2025-08-01","accession":"0001682852-25-000044","full_text":"https://origin.rootz.global/static/filing/0001682852-25-000044.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRNA","company":"Moderna, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":31,"match_count":2,"context":"of such matters is inherently uncertain and often involves significant judgment in assessing risk and estimating potential exposure. While we do not currently expect any pending proceedings to have a material adverse effect on our financial position, results of operations, or cash flows, there can be no assurance that future developments will not have a material impact.On March 3, 2026, we entered into a settlement agre","filed_date":"2026-07-31","accession":"0001682852-26-000150","full_text":"https://origin.rootz.global/static/filing/0001682852-26-000150.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"02a8825dca567e7e60a57236d8e49e5c3c0c0c0ad85588e9a92448f33d3e28c8","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"ce12da4b83598428a753a5f8327dcd6b5f5b846755df57d321a68ff5c8bbd1d3","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":72,"hourly_limit":500,"remaining":428,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}